Related references
Note: Only part of the references are listed.Nintedanib for Systemic Sclerosis-Associated Interstitial Lung Disease
Oliver Distler et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Change in FVC and survival in chronic fibrotic hypersensitivity pneumonitis
Andrea Gimenez et al.
THORAX (2018)
Phenotypic Clusters Predict Outcomes in a Longitudinal Interstitial Lung Disease Cohort
Ayodeji Adegunsoye et al.
CHEST (2018)
Predictors of Mortality in Pulmonary Sarcoidosis
Gamze Kirkil et al.
CHEST (2018)
What's in a name? That which we call IPF, by any other name would act the same
Athol U. Wells et al.
EUROPEAN RESPIRATORY JOURNAL (2018)
Treatment Algorithms for Systemic Sclerosis According to Experts
Andreu Fernandez-Codina et al.
ARTHRITIS & RHEUMATOLOGY (2018)
Associations between comorbidities, their treatment and survival in patients with interstitial lung diseases - a claims data analysis
Larissa Schwarzkopf et al.
RESPIRATORY RESEARCH (2018)
Systemic sclerosis associated interstitial lung disease - individualized immunosuppressive therapy and course of lung function: results of the EUSTAR group
Sabine Adler et al.
ARTHRITIS RESEARCH & THERAPY (2018)
Update of EULAR recommendations for the treatment of systemic sclerosis
Otylia Kowal-Bielecka et al.
ANNALS OF THE RHEUMATIC DISEASES (2017)
Unclassifiable interstitial lung diseases: Clinical characteristics and survival
Charlotte Hyldgaard et al.
RESPIROLOGY (2017)
Rituximab versus cyclophosphamide for the treatment of connective tissue disease-associated interstitial lung disease (RECITAL): study protocol for a randomised controlled trial
Peter Saunders et al.
TRIALS (2017)
Unmet needs in the treatment of idiopathic pulmonary fibrosis-insights from patient chart review in five European countries
Toby M. Maher et al.
BMC PULMONARY MEDICINE (2017)
Progressive Decline of Lung Function in Rheumatoid Arthritis-Associated Interstitial Lung Disease
Jorge A. Zamora-Legoff et al.
ARTHRITIS & RHEUMATOLOGY (2017)
Lung Manifestations in the Rheumatic Diseases
Tracy J. Doyle et al.
CHEST (2017)
Design of the PF-ILD trial: a doubleblind, randomised, placebo-controlled phase III trial of nintedanib in patients with progressive fibrosing interstitial lung disease
Kevin R. Flaherty et al.
BMJ OPEN RESPIRATORY RESEARCH (2017)
A population-based cohort study of rheumatoid arthritis-associated interstitial lung disease: comorbidity and mortality
Charlotte Hyldgaard et al.
ANNALS OF THE RHEUMATIC DISEASES (2017)
Antifibrotic drugs as treatment of nonidiopathic pulmonary fibrosis interstitial pneumonias: the time is now (?)
Michael Kreuter et al.
CURRENT OPINION IN PULMONARY MEDICINE (2017)
Are physicians in primary health care able to recognize pulmonary fibrosis?
Minna Purokivi et al.
EUROPEAN CLINICAL RESPIRATORY JOURNAL (2017)
Idiopathic non-specific interstitial pneumonia
Elizabeth A. Belloli et al.
RESPIROLOGY (2016)
Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial
Donald P. Tashkin et al.
LANCET RESPIRATORY MEDICINE (2016)
An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of Idiopathic Pulmonary Fibrosis An Update of the 2011 Clinical Practice Guideline
Ganesh Raghu et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2015)
Predictors of Mortality and Progression in Scleroderma-Associated Interstitial Lung Disease A Systematic Review
Tiffany A. Winstone et al.
CHEST (2014)
Predictors of mortality in rheumatoid arthritis-related interstitial lung disease
Deborah Assayag et al.
RESPIROLOGY (2014)
Cross-Disciplinary Collaboration in Connective Tissue Disease-Related Lung Disease
Aryeh Fischer et al.
SEMINARS IN RESPIRATORY AND CRITICAL CARE MEDICINE (2014)
Current approaches to the diagnosis and treatment of idiopathic pulmonary fibrosis in Europe: the AIR survey
Vincent Cottin
EUROPEAN RESPIRATORY REVIEW (2014)
An Official American Thoracic Society/European Respiratory Society Statement: Update of the International Multidisciplinary Classification of the Idiopathic Interstitial Pneumonias
William D. Travis et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2013)
Identifying an Inciting Antigen Is Associated With Improved Survival in Patients With Chronic Hypersensitivity Pneumonitis
Evans R. Fernandez Perez et al.
CHEST (2013)
Radiographic Fibrosis Score Predicts Survival in Hypersensitivity Pneumonitis
Joshua J. Mooney et al.
CHEST (2013)
Prevalence and prognosis of unclassifiable interstitial lung disease
Christopher J. Ryerson et al.
EUROPEAN RESPIRATORY JOURNAL (2013)
Idiopathic Nonspecific Interstitial Pneumonia: Changes in High-Resolution Computed Tomography on Long-Term Follow-Up
Mi-Young Kim et al.
JOURNAL OF COMPUTER ASSISTED TOMOGRAPHY (2012)
An Official ATS/ERSARS/ALAT Statement: Idiopathic Pulmonary Fibrosis: Evidence-based Guidelines for Diagnosis and Management
Ganesh Raghu et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2011)
Long-term Course and Prognosis of Idiopathic Pulmonary Fibrosis in the New Millennium
Steven D. Nathan et al.
CHEST (2011)
Incidence, Prevalence, and Clinical Course of Idiopathic Pulmonary Fibrosis A Population-Based Study
Evans R. Fernandez Perez et al.
CHEST (2010)
Usual interstitial pneumonia in rheumatoid arthritis-associated interstitial lung disease
E. J. Kim et al.
EUROPEAN RESPIRATORY JOURNAL (2010)
EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group (EUSTAR)
O. Kowal-Bielecka et al.
ANNALS OF THE RHEUMATIC DISEASES (2009)
Interstitial lung disease in systemic sclerosis - A simple staging system
Nicole S. L. Goh et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2008)
Environmental, inhaled and ingested causes of pulmonary fibrosis
Nasreen Khalil et al.
TOXICOLOGIC PATHOLOGY (2007)
Cyclophosphamide versus placebo in scleroderma lung disease
Donald P. Tashkin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Share Paper
